About
Vogenx
VOGX.US
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D).
Profile
- Company Name
- Vogenx, Inc.
- Market
- NasdaqCM
- Founded
- Industry
- --
- Fiscal Year End
- --
- Website
- vogenx.com